Myoung-Schook Yoou
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Myoung-Schook Yoou has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Chunhwa Ihm
Department of Laboratory Medicine, Daejeon Eulji Medical Center, Eulji University, Daejeon, Korea
2 shared publications - Hyun-Ja Jeong
Biochip Research Center, Hoseo University, Asan, Republic of Korea
2 shared publications Jae-Bum Jang
Department of Pharmaceutical Engineering, Hoseo University, 20, Hoseo-ro 79beon-gil, Baebang-eup, Asan, Chungcheongnam-do 31499, Republic of Korea
2 shared publications- Sun-Young Nam
Department of Plastic and Reconstructive Surgery, Seoul National University Bundang Hospital, Seongnam, Republic of Korea
2 shared publications - Dong Hyun Kim
Department of Dermatology, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam 13496, Republic of Korea
1 shared publication - Eun Hye Choi
Eulji Medi-Bio Research Institute, Eulji University, Daejeon, Korea
1 shared publication
Latest Publications
- Open Access
- 1 January 2025
- Published by Wiley in Canadian Journal of Infectious Diseases and Medical Microbiology
- Vol. 2025 (1)
A Comparative Analysis of Molecular Epidemiology and Antibiotic Resistance in Group B Streptococcus Isolated From Invasive and Noninvasive Adult Cases in Daejeon, South Korea
Background: This study aims to determine the molecular features and antimicrobial resistance of Streptococcus agalactiae (Group B streptococcus, GBS) causing invasive and noninvasive infections in Korean adults. Methods: Sequence type (ST), capsular serotype, pilus island typing, and antimicrobial susceptibility were analyzed for GBS isolates obtained at a hospital laboratory that processed the primary clinical specimens collected from Korean adults between 2021 and 2024. Results: Among the 90 isolates, Serotype VIII (34.4%) was the most common, followed by V (17.8%), Ia (12.2%), VI (11.1%), II (10.0%), and Ib (6.7%). Every isolate contained at least one PI gene, of which PI2a (37.8%) was the most frequently observed combination. The combination of PI1 and PI2b was present in 34.4% of isolates, followed by PI1 and PI2a (24.4%) and PI2b alone (3.3%). Among the 18 STs identified, the capsular serotype VIII/ST2–clonal complex 1 (CC1) was dominant (34.4%), followed by V or VI/ST1 (12.2%). All isolates were susceptible to both ampicillin and vancomycin, while antibiotic resistances were observed for erythromycin (27.8%), levofloxacin (13.3%), clindamycin (25.6%), and tetracycline (47.8%), respectively. Conclusions: These data are key elements to help design prevention and treatment strategies for GBS infection in Korean adults.
- 1 January 2025
- Published by Wiley in Canadian Journal of Infectious Diseases and Medical Microbiology
- Vol. 2025 (1)
Open AccessA Comparative Analysis of Molecular Epidemiology and Antibiotic Resistance in Group B Streptococcus Isolated From Invasive and Noninvasive Adult Cases in Daejeon, South Korea
Background: This study aims to determine the molecular features and antimicrobial resistance of Streptococcus agalactiae (Group B streptococcus, GBS) causing invasive and noninvasive infections in Korean adults. Methods: Sequence type (ST), capsular serotype, pilus island typing, and antimicrobial susceptibility were analyzed for GBS isolates obtained at a hospital laboratory that processed the primary clinical specimens collected from Korean adults between 2021 and 2024. Results: Among the 90 isolates, Serotype VIII (34.4%) was the most common, followed by V (17.8%), Ia (12.2%), VI (11.1%), II (10.0%), and Ib (6.7%). Every isolate contained at least one PI gene, of which PI2a (37.8%) was the most frequently observed combination. The combination of PI1 and PI2b was present in 34.4% of isolates, followed by PI1 and PI2a (24.4%) and PI2b alone (3.3%). Among the 18 STs identified, the capsular serotype VIII/ST2–clonal complex 1 (CC1) was dominant (34.4%), followed by V or VI/ST1 (12.2%). All isolates were susceptible to both ampicillin and vancomycin, while antibiotic resistances were observed for erythromycin (27.8%), levofloxacin (13.3%), clindamycin (25.6%), and tetracycline (47.8%), respectively. Conclusions: These data are key elements to help design prevention and treatment strategies for GBS infection in Korean adults.
- Open Access
- 31 December 2024
- Published by Korean Association of Quality Assurance for Clinical Laboratory in Journal of Laboratory Medicine and Quality Assurance
- Vol. 46 (4) , 208-213
Clinical Performance Evaluation of the Ag Test for Detecting SARS-CoV-2 and Influenza A/B Viruses Using Nasopharyngeal Swabs
Myoung-Schook Yoou, Ji Hun Jeong, Eun-Hye Choi, Yuri Kim, Chunhwa Ihm. Lab Med Qual Assur 2024;46:208-13. https://doi.org/10.15263/jlmqa.2024.46.4.208
- 31 December 2024
- Published by Korean Association of Quality Assurance for Clinical Laboratory in Journal of Laboratory Medicine and Quality Assurance
- Vol. 46 (4) , 208-213
Open AccessClinical Performance Evaluation of the Ag Test for Detecting SARS-CoV-2 and Influenza A/B Viruses Using Nasopharyngeal Swabs
Myoung-Schook Yoou, Ji Hun Jeong, Eun-Hye Choi, Yuri Kim, Chunhwa Ihm. Lab Med Qual Assur 2024;46:208-13. https://doi.org/10.15263/jlmqa.2024.46.4.208
- 1 August 2017
- Published by Elsevier in Food and Chemical Toxicology
- Vol. 106 (Pt A) , 78-85
Ameliorative effect of atractylenolide III in the mast cell proliferation induced by TSLP
- 1 August 2017
- Published by Elsevier in Food and Chemical Toxicology
- Vol. 106 (Pt A) , 78-85
Ameliorative effect of atractylenolide III in the mast cell proliferation induced by TSLP
- 28 August 2014
- Published by Springer Nature in Archives of Pharmacal Research
- Vol. 38 (6) , 1223-1231
Antidepressant effect of Stillen™
Stillen™ has been used to treat patients with gastric mucosal ulcers and has an anti-inflammatory effect. It is well-known that neuro-inflammatory reactions are related to depression. Here we evaluated the antidepressant-like effect of Stillen™ on mice subjected to the forced swimming test (FST). Stillen™ and eupatilin (a major component of Stillen™) significantly decreased immobility times compared with the FST control group. In the Stillen™-administered group, increased levels of 5-hydroxytryptamine (serotonin) and brain-derived neurotrophic factor protein were observed in the hippocampus. Nissl bodies also increased in the hippocampus neuronal cytoplasm of the Stillen™-administered group. Stillen™ decreased levels of interleukin (IL)-1β, IL-6, and tumor necrosis factor-α (at the mRNA and protein levels) in the hippocampus and serum, compared with the control group. In addition, the mRNA expression of estrogen receptor-β increased after Stillen™ administration in the hippocampus. These findings suggest that Stillen™ should be viewed as a candidate antidepressant.
- 28 August 2014
- Published by Springer Nature in Archives of Pharmacal Research
- Vol. 38 (6) , 1223-1231
Antidepressant effect of Stillen™
Stillen™ has been used to treat patients with gastric mucosal ulcers and has an anti-inflammatory effect. It is well-known that neuro-inflammatory reactions are related to depression. Here we evaluated the antidepressant-like effect of Stillen™ on mice subjected to the forced swimming test (FST). Stillen™ and eupatilin (a major component of Stillen™) significantly decreased immobility times compared with the FST control group. In the Stillen™-administered group, increased levels of 5-hydroxytryptamine (serotonin) and brain-derived neurotrophic factor protein were observed in the hippocampus. Nissl bodies also increased in the hippocampus neuronal cytoplasm of the Stillen™-administered group. Stillen™ decreased levels of interleukin (IL)-1β, IL-6, and tumor necrosis factor-α (at the mRNA and protein levels) in the hippocampus and serum, compared with the control group. In addition, the mRNA expression of estrogen receptor-β increased after Stillen™ administration in the hippocampus. These findings suggest that Stillen™ should be viewed as a candidate antidepressant.